The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital will join the new ALS Collaborative Cohort program with a grant from Tambourine, Ben and Divya Silbermann’s philanthropy. The Cohort consists of six US-based organizations that will work together to promote access and inclusion across the ALS landscape.
People with ALS face numerous barriers in attempting to access diagnostics, quality care, drug trials, assistive technology, and more. These barriers are especially challenging to navigate for people from underrepresented communities. The Collaborative Cohort grant will fund expanded work by the Healey Center Research Access Nurse and the Healey Platform Trial Patient Navigator, who educate, inform, and connect patients with the most promising research opportunities available.
The Research Access Nurse and Patient Navigator provide one-on-one meetings to help patients learn about clinical research, consider research options, and find appropriate and exciting opportunities for participation regardless of patient location or previous interactions with the healthcare system. They also develop educational webinars, website materials, and patient-facing materials to reach a broad audience of people with ALS, caregivers, loved ones, and advocates. Through engagement in Tambourine’s ALS Collaborative Cohort, the Healey Center will do even more to engage a diverse group of people with ALS in research and clinical trials.
About the Sean M. Healey & AMG Center for ALS
At the Sean M. Healey & AMG Center for ALS at Mass General, we are on a quest to discover life-saving therapies for all people who are affected by ALS. Launched in November 2018, we are a diverse group of researchers and clinicians determined to accelerate the pace of ALS therapy development.
Under the leadership of Merit Cudkowicz, MD, chief of Neurology, and a Science Advisory Council of international experts, we partner with other experts around the globe to reimagine how to develop the right novel therapies for the right people at the right time. We are grounded in our strong belief in the partnership between people with ALS, caregivers and our team. Together we can design more efficient and more effective clinical trials and broaden access for people with ALS.